Previous 10 | Next 10 |
3 Biotech Penny Stocks to Buy [Or Sell] Today As we approach the end of May, biotech penny stocks are on fire. While there is no one reason for these penny stocks to be seeing sizable gains, we can attribute it to a few potential factors. On one hand, the entire list of penny ...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Big Tesla shortTesla (TSLA) shares were the weakest among the Big Six megacaps in Monday's trading, declining more than 2% and falling back below their 200...
AcelRx Pharmaceuticals, Inc. (ACRX) Q1 2021 Earnings Conference Call May 17, 2021 04:30 PM ET Company Participants Raffi Asadorian - Chief Financial Officer Vince Angotti - Chief Executive Officer Pam Palmer - Chief Medical Officer Conference Call Participants Brandon Folkes - Cantor Fitzgera...
AcelRx Pharmaceuticals (ACRX) shares fall nearly 6% during post-market trading after the company reported first-quarter revenue that missed Wall Street estimates. The company's net revenue during the quarter increased 30.8% to $0.51M, but missed analysts' estimate by $0.55M.The...
AcelRx Pharmaceuticals (ACRX) presents results of a study on the intraoperative administration of DSUVIA (sufentanil sublingual tablet; SST) 30 mcg for the management of acute pain in an ambulatory surgery center for patients undergoing orthopedic surgery under general anesthesia.The primary ...
Study of DSUVIA® Showing Significant Reduction in Postoperative Opioids and Better OBAS Scores Compared to Control Group to be Presented at the American Society of Regional Anesthesia (ASRA) Annual Meeting PR Newswire HAYWARD, Calif. , May 13, 2021 /PRNewswi...
AcelRx to Host First Quarter 2021 Financial Results Call and Webcast on May 17, 2021 PR Newswire HAYWARD, Calif. , May 10, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will rele...
OLINVYK, oliceridine, is Trevena's first approved drug and offers a compelling safety, efficacy, and economic profile versus IV morphine. Revenue growth looks particularly strong, with the potential for triple-digit growth rates in a multi-billion dollar market opportunity. Valuat...
AcelRx Announces an Investigator-Initiated Study of DSUVIA® for Use in Same-Day Total Joint Replacement PR Newswire HAYWARD, Calif. , May 6, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company f...
Gainers: Reviva Pharmaceuticals RVPH +41%, Ocugen OCGN +22%, Axsome Therapeutics AXSM +12%, AcelRx Pharmaceuticals (ACRX) +9%, Voyager Therapeutics VYGR +8%.Losers: MiMedx (MDXG) -9%, Shineco (TYHT) -8%, Brooklyn ImmunoTherapeut...
News, Short Squeeze, Breakout and More Instantly...
AcelRx Pharmaceuticals Inc. Company Name:
ACRX Stock Symbol:
NASDAQ Market:
AcelRx Pharmaceuticals Inc. Website:
AcelRx Announces Rebranding With Name Change to Talphera, Inc. PR Newswire Name change to "Talphera" reflects a new era of the Company in partnership with the medical community developing novel solutions for medically supervised settings Talphera will begin trading on ...
AcelRx Pharmaceuticals Announces Publication of Study Evaluating Anticoagulation Practices for Continuous Renal Replacement Therapy in the United States PR Newswire Use of CRRT increased during COVID and remained at these higher utilization levels Study results demonst...
AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate Update PR Newswire Niyad™ Investigational Device Exemption (IDE) approval by the FDA achieved in third quarter Company plans to begin its Niyad registrational study this quarter with topl...